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Objectives: Activity of rifampicin against Propionibacterium acnes biofilms was recently demonstrated, but
rifampicin resistance has not yet been described in this organism. We investigated the in vitro emergence of
rifampicin resistance in P. acnes and characterized its molecular background.
Methods: P. acnes ATCC 11827 was used (MIC 0.007 mg/L). The mutation rate was determined by inoculation of
109 cfu of P. acnes on rifampicin-containing agar plates incubated anaerobically for 7 days. Progressive emer-
gence of resistance was studied by serial exposure to increasing concentrations of rifampicin in 72 h cycles
using a low (106 cfu/mL) and high (108 cfu/mL) inoculum. The stability of resistance was determined after
three subcultures of rifampicin-resistant isolates on rifampicin-free agar. For resistant mutants, the whole
rpoB gene was amplified, sequenced and compared with a P. acnes reference sequence (NC006085).
Results: P. acnes growth was observed on rifampicin-containing plates with mutation rates of 2+1 cfu×1029
(4096×MIC) and 12+5 cfu×1029 (4×MIC). High-level rifampicin resistance emerged progressively after 4 (high
inoculum) and 13 (low inoculum) cycles. In rifampicin-resistant isolates, the MIC remained .32 mg/L after
three subcultures. Mutations were detected in clusters I (amino acids 418–444) and II (amino acids 471–
486) of the rpoB gene after sequence alignment with a Staphylococcus aureus reference sequence
(CAA45512). The five following substitutions were found: His-437Tyr, Ser-442Leu, Leu-444Ser, Ile-
483Val and Ser-485Leu.
Conclusion: The rifampicin MIC increased from highly susceptible to highly resistant values. The resistance
remained stable and was associated with mutations in the rpoB gene. To our knowledge, this is the first
report of the emergence of rifampicin resistance in P. acnes.
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Introduction
Propionibacterium acnes is increasingly recognized as the cause
of foreign-body infections, including those involving prosthetic
joints, spine hardware and ventriculo-peritoneal shunts.1–3
P. acnes is highly susceptible to a wide range of antimicrobials,
including clindamycin, b-lactams and quinolones.4 However,
the optimal treatment regimen of P. acnes biofilm infections
has not been defined. The efficiency of rifampicin for the eradica-
tion of P. acnes biofilms has been demonstrated in vitro5 and, re-
cently, in vivo in an animal model of foreign-body infection.6
Rifampicin acts by interacting with the b-subunit of the bac-
terial RNA polymerase encoded by the rpoB gene.7 Alignment
of the rpoB gene sequence from different species has confirmed
conserved domains among the sequences.8 Resistance to
rifampicin has been described in several bacterial species, such
as Staphylococcus aureus,9 Escherichia coli,10 Streptococcus
pyogenes11 and Mycobacterium tuberculosis.12 Resistance is
generally due to point mutations in the rpoB gene leading to a
reduced binding between the antibiotic and the enzyme.
Mutations particularly occur in the conserved domains of
cluster I (amino acids 507–533), cluster II (amino acids 563–
572) and cluster III (amino acids 684–690), according to
E. coli numbering.13
The aim of this study was to investigate the emergence of ri-
fampicin resistance in P. acnes in vitro and whether combination
with an additional antimicrobial agent can prevent the emer-
gence of rifampicin resistance. In addition, the molecular back-
ground of rifampicin resistance in P. acnes isolates was
characterized.
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Materials and methods
Study organism
All experiments were performed with P. acnes strain ATCC 11827. The
MICs of rifampicin, clindamycin, penicillin G, daptomycin and levofloxacin
were 0.007, 0.125, 0.03, 1 and 1 mg/L, respectively.6 Bacteria were stored
at 2708C by using the cryovial bead preservation system (Microbank;
Pro-Lab Diagnostics, Richmond Hill, Ontario, Canada). For inoculum prep-
aration, one bead was spread on a blood agar plate and incubated for
72 h. One distinct colony was resuspended in 10 mL of reduced brain
heart infusion (BHI) and incubated at 378C for another 72 h. All incuba-
tions were performed in anaerobic conditions using an AnaeroGenTM
system (Oxoid, Basingstoke, Hampshire, UK) at 378C.
Antimicrobial agents
Rifampicin powder (prepared in sterile water, 60 mg/mL; Sandoz AG,
Steinhausen, Switzerland), clindamycin powder (prepared in sterile
water 200 mg/mL; Sigma), levofloxacin solution (5 mg/mL; Sanofi
Aventis Pharma AG, Zurich, Switzerland) and penicillin G (25 mg/mL; Gru¨-
nenthal Pharma AG, Mitlo¨di, Switzerland) were purchased from the re-
spective manufacturers. Daptomycin powder was supplied by Novartis
Pharma AG (Bern, Switzerland). A stock solution of 50 mg/mL was pre-
pared in sterile 0.9% saline.
Rifampicin resistance studies
For the analysis of spontaneous rifampicin resistance, agar-based single-
step mutation studies were performed, as previously described.14
Brucella agar supplemented with vitamin K, haemin and horse blood pre-
pared according to CLSI M11-A7 guidelines was used.15 Briefly, a large in-
oculum (109 cfu) of the bacteria was spread on Brucella agar plates
containing rifampicin concentrations of 4× and 4096× MIC, correspond-
ing to 0.03 and 32 mg/L, respectively. The lower concentration corre-
sponded to an increased MIC that is still in the susceptible range
(0.03 mg/L) and the higher concentration corresponded to full resistance
(32 mg/L). The plates were incubated for 5–7 days before the colonies
were enumerated. The spontaneous resistance rate was calculated
from the number of colonies that grew on plates containing drug
versus the number of colonies that grew on drug-free agar.
For progressive rifampicin resistance selection, a protocol adapted
from Entenza et al.16,17 was used. Briefly, bacteria were exposed to
serial 2-fold increasing concentrations of rifampicin in BHI for a total of
10 cycles, each cycle being 72 h. A series of tubes containing 2-fold in-
creasing concentrations of rifampicin were inoculated with either 106
or 108 cfu/mL (final concentration). Following incubation, the MIC of
rifampicin was read and 1 mL (for 108 cfu/mL) or 0.1 mL (for
106 cfu/mL) samples from the tubes containing the highest antibiotic
concentration, and still showing turbidity, were used to inoculate a new
series of tubes containing antibiotic dilutions. The experiments were per-
formed twice.
To investigate whether a secondary agent could prevent the emer-
gence of rifampicin resistance, experiments were performed as described
above in the presence of 0.25× MIC of daptomycin, clindamycin, levo-
floxacin or penicillin G, for a total of 10 cycles using an inoculum of
106 cfu/mL. A subinhibitory concentration of the second drug was used
to allow bacterial growth. The MIC of rifampicin was read after each
cycle. After the last cycle, the MICs of the combination drugs were deter-
mined by macrobroth dilution, as previously described.6 For combination
studies including daptomycin, growth media were supplemented with
50 mg/L Ca2+.
The stability of all rifampicin-resistant isolates was confirmed by sub-
culture on rifampicin-free agar three times. The MIC of rifampicin was
then retested by Etest (bioMe´rieux SA, Marcy l’Etoile, France) using an in-
oculum of 1 McFarland and anaerobic incubation for 48 h. All resistant
isolates were identified by biochemical tests and confirmed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry
with a Bruker Daltonic mass spectrometer.
Detection of mutations in the rpoB gene in
rifampicin-resistant P. acnes isolates
Total DNA from P. acnes ATCC 11827 and isogenic resistant isolates
was extracted using the InstaGene Matrix method (Bio-Rad Laboratories,
Hercules, CA, USA). The procedure was performed according to the man-
ufacturer’s instructions. After centrifugation, the supernatant was used
as DNA template for PCR analysis.
The whole rpoB gene, including the rifampicin resistance-determining
region in the rpoB gene of E. coli10 and S. aureus,18 was amplified by PCR.
Different sets of primers were designed according to the sequence align-
ment of four strains (GenBank accession numbers CP002815, CP002409,
NC006085 and CP001977) and are presented in Table 1. Six overlapping
regions of the rpoB gene from P. acnes were amplified: a 571 bp fragment
from nucleotide positions +12 to +582; a 708 bp fragment from nucleo-
tide positions +484 to +1191; a 693 bp fragment from nucleotide posi-
tions +1113 to +1805; a 636 bp fragment from nucleotide positions
+1751 to +2386; a 656 bp fragment from nucleotide positions +2320
to +2975; and a 561 bp fragment from nucleotide positions +2912 to
+3472, corresponding to the whole genome (P. acnes coordinates
using P. acnes KPA171202; GenBank accession number NC006085).19
PCR was performed in a final volume of 50 mL containing 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 200 mM of each nucleotide,
0.5 mM of each primer and 2.5 U of Taq DNA polymerase (Phusionw High-
Fidelity DNA Polymerase; Finnzymes, Illkirch, France). The PCR conditions
were as follows: a 90 s first step of denaturation at 948C, 30 cycles with
60 s of denaturation at 948C, 60 s of hybridization at 558C and 60 s of ex-
tension at 728C, with a final extension step of 7 min at 728C.
The PCR fragments were purified and sequenced using the ABI PRISM
BigDye Terminator v1.1 Cycle Sequencing Ready Reaction Kit (Applied Bio-
systems, Courtaboeuf, France). Sequence analysis was performed on a
3130XL Genetic Analyzer DNA sequencer (Applied Biosystems, Courta-
boeuf, France). The sequence of the rpoB gene was compared with that
of the rpoB gene of the P. acnes reference strain (GenBank accession
number NC006085) using different free software available on the
Table 1. Primers designed to amplify and sequence the rpoB gene of
P. acnes
Primer Primer sequence (5′3′) Locationa
PARI-1 CCATAGCGTTGTCGGCAC +3472 to 3455
PARI-2 GGTGTCAACGAGCATCTCG +2975 to 2958
PARI-3 CCGGTTTGCTGCAGTACG +2912 to 2930
PARI-4 CCTTCGGAGTGACCTTGC +2386 to 2369
PARI-5 GGCATCGTGCGTATCGGT +2320 to +2337
PARI-6 GCTGCATATTCGCGCCCA +1805 to +1788
PARI-7 CCATTCCTCGAGCACGAC +1751 to 1770
PARI-8 GGCCTCAATGTCCTGCGT +1191 to +1174
PARI-9 CCAGAACCAGTTGCGTACC +1113 to +1132
PARI-10 CGACGGGATCACCTTACAG +582 to 564
PARI-11 TGGTGTCCCAGTTGGTGC +484 to +502
PARI-12 GCGTACCGCGTCGAAGAA +12 to +29
aAccording to the P. acnes rpoB gene reference sequence.
Furustrand Tafin et al.
524
256
128
64
32
16
8
4
2
1
0.5
0.25
0.125
0.06
0.03
0.15
0.007
0.004
0.002
1 2 3 4 5 6 7 8 9 10
Cycle (×72 h)
11 12 13 14 15 16 17 18 19 20
Ri
fa
m
pi
ci
n 
(m
g/
L)
108 cfu/mL
106 cfu/mL
1 2 3 4 5 6 7 8 9 10
Cycle (×72 h)
RIF
RIF + DAP
RIF + PEN
RIF + LVX
RIF + CLI
Ri
fa
m
pi
ci
n 
(m
g/
L)
0.002
0.004
0.007
0.015
0.03
0.06
0.125
0.25
0.5
1
2
4
8
16
32
64
128
256
(a)
(b)
Figure 1. Progressive emergence of rifampicin (RIF) resistance in P. acnes using two different inocula (a) and in combination with 0.25× MIC of
daptomycin (DAP), levofloxacin (LVX), clindamycin (CLI) or penicillin G (PEN) using an inoculum of 106 cfu/mL (b).
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Internet (http://blast.ncbi.nlm.nih.gov/Blast.cgi, http://www.genome.jp/
tools/clustalw/ and http://web.expasy.org/translate/).
Results
Resistance studies
To determine the rate of spontaneous emergence of resistance,
bacteria were exposed to rifampicin concentrations equal to 4×
and 4096× MIC (0.03 and 32 mg/L). The mutation rate was
12+5×1029 and 2+1×1029 cfu for the low and high rifampicin
concentrations, respectively. After three subcultures on rifampicin-
free agar plates, the MIC remained 0.03 and .32 mg/L, as deter-
mined by Etest for the P. acnes derived from plates containing 4×
and 4096× MIC of rifampicin, respectively.
Figure 1(a) demonstrates the results of rifampicin resistance
selection during continuous exposure of bacteria to 2-fold in-
creasing concentrations of rifampicin using two different
inocula, 108 and 106 cfu/mL. An increase in the MIC was
rapidly observed when using a high bacterial concentration,
with an MIC of 32 mg/L being observed after four cycles. With
a lower inoculum, the MIC increased gradually, with full resist-
ance (MIC 32 mg/L) being observed after 13 cycles.
The addition of a secondary agent did not prevent resistance
development when using a high inoculum (data not shown).
Figure 1(b) shows the selection of rifampicin resistance, alone
and in combination with 0.25× MIC of clindamycin, penicillin G,
levofloxacin and daptomycin, using an inoculum of 106 cfu/mL.
The addition of clindamycin, levofloxacin and penicillin G to the
cultures prevented the selection of highly resistant isolates
during 10 cycles and the MIC remained,0.06 mg/L. Daptomycin
delayed the increase in the MIC of rifampicin, but did not prevent
the emergence of resistance. No increase in the MICs of the sec-
ondary antimicrobials used in the combination studies was
observed.
Molecular characterization of the rpoB gene in
rifampicin-resistant isolates
The rpoB gene of rifampicin-resistant P. acnes isolates, deriving
from plates containing 0.03 mg/L (named PARif1–2, exhibiting
reduced susceptibility) and 32 mg/L (named PARif3–5, expres-
sing resistance), and from cycle 10 in the cycling experiment
using a high inoculum (named PARif6, expressing resistance),
was sequenced. The five different amino substitutions detected
in the isolates are summarized in Table 2. Figure 2 shows the align-
ment of the rpoB gene sequences, including clusters I and II, of
E. coli (GenBank accession number EG10894),20 M. tuberculosis
(GenBank accession number L27989),21 S. aureus (GenBank acces-
sion number X64172)22,23 and P. acnes (GenBank accession
number NC006085)19 reference strains. The amino acid substitu-
tions found in P. acnes are indicated by arrows, and previously
described mutations in other species are underlined and in bold.
Sequencing of isolates deriving from previous cycles (cycles
3–10) in the cycling experiment revealed that the amino acid
substitutions in PARif6 Ser-442Leu (cluster I) and
Ile-483Val (cluster II) had occurred after four and nine
cycles of exposure, respectively.
Discussion
We describe, for the first time to our knowledge, the amino acid
substitutions conferring rifampicin resistance in P. acnes. Three
substitutions were detected in cluster I of the rpoB gene asso-
ciated with either high- or low-level resistance. Interestingly, the
position of the amino acid change His-437Tyr found in PARif3
and PARif4 (MIC 32 mg/L) corresponded to the position of the
His-481Tyr substitution conferring high-level rifampicin resist-
ance in S. aureus.9,18 In M. tuberculosis, mutations conferring
rifampicin resistance are mainly located in an 81 bp hot-spot
region of cluster I.12 Sequence alignment of the rpoB gene of
M. tuberculosis and P. acnes revealed that the substitutions
Ser-442Leu (PARif6) and Leu-444Ser (PARif2), associated
with high and low resistance, respectively, were located within
this conserved region. Two amino acid changes were detected in
cluster II: Ile-483Val and Ser-485Leu, of which the first
was a secondary mutation in the already resistant P. acnes
isolate, PARif6, and the second was detected in an isolate exhibit-
ing only low-level resistance. These codons (483 and 485) corres-
pond to codons previously described to confer rifampicin
resistance in S. aureus (527 and 529)18 and E. coli (572 and 574).10
During progressive exposure to rifampicin, a double-mutant
was obtained and sequencing demonstrated that the first muta-
tion (Ser-442Leu) occurred in cluster I after four cycles of
exposure, leading to a major increase in the rifampicin MIC,
whereas the second mutation (Ile-483Val) occurred in cluster
II after nine cycles of exposure and did not increase the MIC
further. The frequency of the Ile-483Val mutation is presum-
ably lower and could imply there is a fitness cost associated
with the drug resistance.24
We observed that rifampicin resistance emerged rapidly, if the
bacterial load was high, expressing a mutation rate of
2+1×1029. Compared with rifampicin resistance mutation
rates of 1027–1028 in S. aureus and E. coli,9,25 the low mutation
rate in P. acnesmay reflect its slow growth rate. Mutation rates in
high-density P. acnes biofilms have not yet been investigated.
The emergence of rifampicin resistance in P. acnes biofilms
needs further investigation, since this risk has important conse-
quences in the treatment of implant-associated infections,
such as prosthetic valve endocarditis, neurosurgical shunt and
prosthetic joint infections.
Table 2. Amino acid substitutions found in rifampicin-resistant P. acnes
isolates
Isolate
Rifampicin MIC
(mg/L)a
Amino acid
substitution
GenBank accession
number
PARif1 0.03 Ser-485Leu JX501524
PARif2 0.03 Leu-444Ser JX501525
PARif3 .32 His-437Tyr JX501526
PARif4 .32 His-437Tyr JX501526
PARif5 .32 Ser-442Leu JX501527
PARif6 .256 Ser-442Leu JX501528
Ile-483Val
aThe MIC was determined by Etest, except for PARif6, where microbroth
dilution was used.
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To prevent the emergence of resistance, rifampicin is adminis-
tered in combination with another antimicrobial agent. In an
animal model of foreign-body infection, the emergence of rifam-
picin resistance in methicillin-resistant S. aureus was prevented
when the drug was administered in combination with levofloxa-
cin or daptomycin.26 In this study, we investigated the potential
of levofloxacin and daptomycin, as well as two other antimicro-
bials commonly used in the treatment of P. acnes infections (clin-
damycin and penicillin G), for preventing the emergence of
rifampicin resistance in vitro. High-level rifampicin resistance
was prevented by the addition of clindamycin, levofloxacin and
penicillin G when the bacterial inoculum was in the range of
106 cfu/mL, whereas none of the antimicrobials tested was
able to prevent resistance if the bacterial concentration was ele-
vated (108 cfu/mL). Daptomycin was not able to completely
prevent rifampicin resistance; however, no increase in the MIC
of daptomycin was observed despite continuous exposure to a
subinhibitory concentration of the drug.
The impact of rifampicin resistance in P. acnes in clinical prac-
tice is unknown. Importantly, the rifampicin resistance in our ex-
perimental setting was stable when the antibiotic pressure was
removed, both for low-level and high-level resistance. In future
studies, testing of the stable isolates in a foreign-body infection
animal model, which was adapted for P. acnes,6 will allow inves-
tigation of the influence of low- and high-level rifampicin resist-
ance on the treatment outcome. In addition, the use of
rifampicin combinations, especially with clindamycin, levofloxa-
cin and penicillin G, needs to be evaluated in vivo to determine
the potential of these antimicrobials for the prevention of
resistance.
In conclusion, we demonstrated that rifampicin resistance
in P. acnes can easily be selected in vitro and can be prevented
by combination with levofloxacin, clindamycin and penicillin G.
Rifampicin resistance was associated with point mutations con-
centrated in clusters I and II of the rpoB gene and occurred in
codons conferring rifampicin resistance in other bacterial species.
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